中华肾脏病杂志2024,Vol.40Issue(1) :61-66.DOI:10.3760/cma.j.cn441217-20230413-00420

血液透析患者瘙痒症的发病机制及药物治疗进展

Advances in pathogenesis and drug therapy in hemodialysis patients with pruritus

汤晓静 梅长林
中华肾脏病杂志2024,Vol.40Issue(1) :61-66.DOI:10.3760/cma.j.cn441217-20230413-00420

血液透析患者瘙痒症的发病机制及药物治疗进展

Advances in pathogenesis and drug therapy in hemodialysis patients with pruritus

汤晓静 1梅长林1
扫码查看

作者信息

  • 1. 海军军医大学第二附属医院肾脏病科,上海 200003
  • 折叠

摘要

慢性肾脏病相关性瘙痒症(chronic kidney disease-associated pruritus,CKD-aP)是血液透析患者常见且难以忍受的并发症,不仅严重影响其生活质量和身心健康,而且增加其远期死亡风险.CKD-aP的发病机制仍不明确,免疫炎症失调、内源性阿片类系统失衡、代谢产物异常蓄积、皮肤干燥症、组胺水平异常、甲状旁腺功能亢进等因素都被证实与其相关.CKD-aP目前缺乏满意、特效的治疗策略,主要包括药物治疗、非药物治疗和透析方式调整.该文主要就CKD-aP的发病机制及药物治疗进展作一综述.

Abstract

Chronic kidney disease-associated pruritus(CKD-aP),one of the most common and intolerable complications in hemodialysis patients,not only seriously affects patients'quality of life and physical and mental health,but also increases the risk of long-term mortality.The pathogenesis of CKD-aP remains unclear,and immune-inflammatory dysregulation,imbalance of endogenous opioid system,abnormal accumulation of metabolites,xerosis,abnormal histamine level as well as hyperparathyroidism,have all been shown to be associated with pruritus.There is a lack of satisfactory and effective treatment strategies for CKD-aP,which mainly include pharmacological treatment,non-pharmacological treatment and dialysis modality modification.This article mainly reviews recent advances in the pathogenesis and pharmacological treatment of pruritus among hemodialysis patients.

关键词

肾透析/瘙痒症/药物疗法/发病机制

Key words

Renal dialysis/Pruritus/Drug therapy/Pathogenesis

引用本文复制引用

出版年

2024
中华肾脏病杂志
中华医学会

中华肾脏病杂志

CSTPCD北大核心
影响因子:1.182
ISSN:1001-7097
参考文献量1
段落导航相关论文